More specifically, a higher mortality is described for anti-GABABR encephalitis (41.7%), followed by anti-NMDAR encephalitis (4–10%), and anti-LGI1 encephalitis (2.8%) [35–37]. This evidence concerns the gene LGI1 and encephalitis.